ATE343380T1 - Verbessertes transdermales abgabesystem - Google Patents

Verbessertes transdermales abgabesystem

Info

Publication number
ATE343380T1
ATE343380T1 AT03766330T AT03766330T ATE343380T1 AT E343380 T1 ATE343380 T1 AT E343380T1 AT 03766330 T AT03766330 T AT 03766330T AT 03766330 T AT03766330 T AT 03766330T AT E343380 T1 ATE343380 T1 AT E343380T1
Authority
AT
Austria
Prior art keywords
functional drug
amine functional
matrix
drug
tds
Prior art date
Application number
AT03766330T
Other languages
English (en)
Inventor
Mike Hannay
Dietrich Wilhelm Schacht
Hans-Michael Wolff
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Application granted granted Critical
Publication of ATE343380T1 publication Critical patent/ATE343380T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03766330T 2002-07-30 2003-07-28 Verbessertes transdermales abgabesystem ATE343380T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02016864A EP1386604A1 (de) 2002-07-30 2002-07-30 Verbessertes transdermales Verabreichungssystem

Publications (1)

Publication Number Publication Date
ATE343380T1 true ATE343380T1 (de) 2006-11-15

Family

ID=30011092

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03766330T ATE343380T1 (de) 2002-07-30 2003-07-28 Verbessertes transdermales abgabesystem

Country Status (21)

Country Link
EP (2) EP1386604A1 (de)
JP (1) JP4837915B2 (de)
KR (1) KR101016914B1 (de)
CN (1) CN100558350C (de)
AT (1) ATE343380T1 (de)
AU (1) AU2003266252B2 (de)
BR (1) BR0313092A (de)
CA (1) CA2490573C (de)
CY (1) CY1105878T1 (de)
DE (1) DE60309329T2 (de)
DK (1) DK1524971T3 (de)
ES (1) ES2273042T3 (de)
IL (1) IL165917A (de)
MX (1) MXPA05000349A (de)
NO (1) NO334187B1 (de)
NZ (1) NZ537476A (de)
PL (1) PL376999A1 (de)
PT (1) PT1524971E (de)
SI (1) SI1524971T1 (de)
WO (1) WO2004012719A1 (de)
ZA (1) ZA200500255B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
EP1386605A1 (de) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Verbessertes transdermales System für die Verabreichung von Rotigotin
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
ES2648197T3 (es) 2008-02-27 2017-12-29 Hisamitsu Pharmaceutical Co., Inc. Parche medicado
US9155725B2 (en) 2008-02-27 2015-10-13 Hisamitsu Pharmaceutical Co., Inc. Adhesive skin patch and packaged product
CN104189912A (zh) * 2009-12-22 2014-12-10 优时比制药有限公司 用于使非结晶形式的罗替戈汀的固体分散体稳定化的聚乙烯吡咯烷酮
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
US10046151B2 (en) 2013-07-03 2018-08-14 Lts Lohmann Therapie-Systeme, Ag Transdermal therapeutic system with electronic component
US11633367B2 (en) 2014-05-20 2023-04-25 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
WO2015177212A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
WO2015177209A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
EP3854388B1 (de) 2020-01-24 2023-10-04 Luye Pharma Switzerland AG Transdermales therapeutisches system mit dem wirkstoff rotigotin und mindestens einem nicht aminresistenten silikonkleber
EP3949956A1 (de) * 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamin-suspensions-tts

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
IT1311696B1 (it) * 1999-06-22 2002-03-19 Zanussi Elettromecc Compressore del fluido frigorigeno azionato da un motore elettricoa frequenza di alimentazione variabile
JP2002045699A (ja) * 2000-08-08 2002-02-12 Mitsubishi Electric Corp 排ガス浄化用層状電気化学触媒
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
CA2441064A1 (en) * 2001-03-16 2002-09-26 Andrx Corporation Controlled release sulfonylurea formulation
JP5354763B2 (ja) * 2001-03-16 2013-11-27 アルザ・コーポレーシヨン フェンタニルを投与するための経皮的張り付け剤
DK1256340T3 (da) * 2001-05-08 2003-12-01 Sanol Arznei Schwarz Gmbh Forbedret transdermalt, terapeutisk system til behandlingen af Parkinsons sygdom
EP1386605A1 (de) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Verbessertes transdermales System für die Verabreichung von Rotigotin

Also Published As

Publication number Publication date
AU2003266252B2 (en) 2008-11-20
NO20050770L (no) 2005-02-11
HK1083458A1 (zh) 2006-07-07
EP1386604A1 (de) 2004-02-04
EP1524971B1 (de) 2006-10-25
CA2490573A1 (en) 2004-02-12
KR20050025638A (ko) 2005-03-14
NO334187B1 (no) 2014-01-13
CN1671365A (zh) 2005-09-21
JP2005535686A (ja) 2005-11-24
SI1524971T1 (sl) 2007-02-28
CY1105878T1 (el) 2011-02-02
ZA200500255B (en) 2006-01-25
DK1524971T3 (da) 2007-02-19
AU2003266252A1 (en) 2004-02-23
IL165917A0 (en) 2006-01-15
DE60309329D1 (de) 2006-12-07
PL376999A1 (pl) 2006-01-23
CA2490573C (en) 2011-06-07
PT1524971E (pt) 2007-01-31
NZ537476A (en) 2007-08-31
BR0313092A (pt) 2005-06-21
MXPA05000349A (es) 2005-03-31
DE60309329T2 (de) 2008-04-17
EP1524971A1 (de) 2005-04-27
CN100558350C (zh) 2009-11-11
JP4837915B2 (ja) 2011-12-14
ES2273042T3 (es) 2007-05-01
IL165917A (en) 2007-07-24
WO2004012719A1 (en) 2004-02-12
KR101016914B1 (ko) 2011-02-22

Similar Documents

Publication Publication Date Title
DK1524975T3 (da) Forbedret, transdermalt tilförselssystem til indgivelse af rotigotin
DK1524971T3 (da) Forbedret transdermalt leveringssystem
DK1418894T3 (da) Transdermalt terapeutisk system med fentanyl
TW570815B (en) Transdermal therapeutic system (TTS) containing the active substance fentanyl
NO20001003D0 (no) Transdermalt terapeutisk system omfattende et trykksensitivt adhesivt reservoarsjikt og et unidireksjonalt elastisk dekksjikt
DE60314298D1 (de) Therapeutisches pflaster mit capsaicin-haltiger polysiloxan-matrix
MY105347A (en) Transdermal therapeutic system comprising as active component buprenorphine
PH12012501165A1 (en) Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer
WO2001068060A3 (de) Stabilisierte übersättigte transdermale therapeutische matrixsysteme
DK0474647T3 (da) Fremgangsmåde og indretning til frigivelse af lægemidler til huden
DK1143938T3 (da) Transdermalt terapeutisk system med en selvklæbende matrix, der indeholder organiske syreadditionssalte af alkaloider af morphin- eller morphin-type
DK1251853T3 (da) Transdermalt terapeutisk system til indgivelse af zaleplon
MY110391A (en) Nitroglycerin-containing patch, a process for the production and the use thereof
DK1011674T3 (da) Transdermalt terapeutisk system indeholdende det aktive stof af scopolaminbase
BRPI0011135B8 (pt) sistema de ministração terapêutica transdérmica contendo agente neuroléptico
DE50313224D1 (de) Pflaster, enthaltend Fentanylum

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1524971

Country of ref document: EP

EEIH Change in the person of patent owner